Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Colorcon
Cipla
Express Scripts
Cerilliant
Chubb
Mallinckrodt
Medtronic
Accenture
Julphar

Generated: October 21, 2017

DrugPatentWatch Database Preview

OXYTROL Drug Profile

« Back to Dashboard

Which patents cover Oxytrol, and when can generic versions of Oxytrol launch?

Oxytrol is a drug marketed by Allergan Sales Llc and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in twenty countries.

The generic ingredient in OXYTROL is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.

Summary for Tradename: OXYTROL

US Patents:6
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list52
Clinical Trials: see list4
Patent Applications: see list2,951
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OXYTROL at DailyMed

Pharmacology for Tradename: OXYTROL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OXYTROL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003► Subscribe► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003► Subscribe► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for OXYTROL

Drugname Dosage Strength RLD Submissiondate
oxybutyninTransdermal System Extended-re3.9 mg/24 hrsOxytrol8/19/2008

Non-Orange Book Patents for Tradename: OXYTROL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,029,694Compositions and methods for transdermal oxybutynin therapy► Subscribe
8,241,662Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy► Subscribe
7,087,241Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OXYTROL

Country Document Number Estimated Expiration
Australia2003287377► Subscribe
Japan6209263► Subscribe
Japan2012046526► Subscribe
Australia2001253782► Subscribe
Norway20052625► Subscribe
China1708269► Subscribe
European Patent Office2612629► Subscribe
World Intellectual Property Organization (WIPO)2004041187► Subscribe
European Patent Office2322170► Subscribe
South Africa200503316► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
McKinsey
Merck
UBS
Chubb
Medtronic
AstraZeneca
Citi
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot